All In Biotech

Drug Trial Radar · NCT00223925

Maribavir for Prevention of CMV After Stem Cell Transplants

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, and Prophylactic Anti-cytomegalovirus Activity of Maribavir in Recipients of Allogeneic Stem Cell Transplants

Last checked: Nov 19, 2026Latest source record: May 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Actual

Start

Oct 28, 2004

Primary completion

Apr 5, 2006

Study completion Apr 5, 2006

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 22, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug with a novel mechanism of action compared to currently available anti-CMV drugs. This study will test the safety and anti-CMV activity of different doses of maribavir when given as CMV prophylaxis following stem cell transplants.

Conditions

  • Cytomegalovirus Infection

Interventions

  • MaribavirDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical safety as measured by the recording of treatment emergent adverse eventsTime frame: 13 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California

  • UCLA Medical Center

    Los Angeles, California

  • Loyola University

    Maywood, Illinois

  • Tufts-New England Medical Center

    Boston, Massachusetts

  • Wayne State Medical Center

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Duke Medical Center

    Durham, North Carolina

  • Baylor University Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.